Skip to main content
Premium Trial:

Request an Annual Quote

Eone-Diagnomics, Cordlife Ink NIPT Deal

NEW YORK (GenomeWeb) – Eone-Diagnomics Genome Center (EDGC) announced today that it has signed an agreement to offer its Gen Screen non-invasive prenatal test in certain Asian markets in partnership with cord blood service provider Cordlife.

Under the terms of the deal, EDGC — joint venture between San Diego-based bioinformatics firm Diagnomics and South Korea's Eone Life Science Institute — will service the test in the Philippines and Indonesia through Singapore-based Cordlife's sales networks in those nations. EDGC said it anticipates expanding the relationship later to include additional Asian countries and its other products such as the DTC genetic test Gene2me and the ophthalmology genetic test Myeyegene.

Additional terms were not disclosed.

Earlier this year, EDGC partnered with Chinese genetic analysis company GPBio to develop and expand consumer and clinical genomic services for Asian markets.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.